[(5E)-13,13-dimethoxy-4-tricyclo[8.2.1.02,9]tridec-5-enyl] N-methylcarbamate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [(5E)-13,13-dimethoxy-4-tricyclo[8.2.1.02,9]tridec-5-enyl] N-methylcarbamate
• 化学式: C₁₇H₂₇NO₄
• 分子量: 309.4
• InChiKey: YQXHLMXBNUEIGL-GQCTYLIASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• BIO-ORTHOGONAL DRUG ACTIVATION
  申请人：KONINKLIJKE PHILIPS N.V.

  公开号：US20160106859A1

  公开（公告）日：2016-04-21

  The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.

  该发明涉及一种用于治疗学的原药激活方法，其中使用了表现出彼此生物正交反应性的非生物活性化学基团。该发明还涉及一种包含至少一种原药和至少一种激活剂的试剂盒，其中原药包含药物和第一个生物正交反应基团（触发器），而激活剂包含第二个生物正交反应基团。该发明还涉及在上述方法和试剂盒中使用的靶向治疗剂。该发明特别适用于抗体药物偶联物和双特异性及三特异性抗体衍生物。
• [EN] BIO-ORTHOGONAL DRUG ACTIVATION<br/>[FR] ACTIVATION DE MÉDICAMENT BIO-ORTHOGONALE
  申请人：TAGWORKS PHARMACEUTICALS B V

  公开号：WO2014081301A1

  公开（公告）日：2014-05-30

  Disclosed is a kit for the administration and activation of a Prodrug. The kit comprises a Masking Moiety linked, directly or indirectly, to a Trigger moiety, which in turn is linked to a Drug, and an Activator for the Trigger moiety. The Trigger moiety comprises a dienophile and the Activator comprises a diene, whereby the dienophile is an eight-membered non- aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The Trigger and the Activator undergo a fast, bio-orthogonal reaction resulting in the release of the Masking Moiety, and activation of the drug.

  揭示了一种用于给予和激活前药的工具包。该工具包包括一个掩蔽基团，直接或间接地连接到一个触发基团，该触发基团又连接到一种药物，以及一个用于触发基团的激活剂。触发基团包括一个二烯烃，激活剂包括一个二烯，其中二烯烃是一个八元非芳香环烯基团，优选为环辛烯基团，更优选为反式环辛烯基团。触发基团和激活剂经历一个快速的生物正交反应，导致掩蔽基团的释放和药物的激活。
• CHEMICALLY CLEAVABLE GROUP
  申请人：TAGWORKS PHARMACEUTICALS B.V.

  公开号：US20150344514A1

  公开（公告）日：2015-12-03

  Disclosed is the use of the reactive components of the inverse electron-demand Diels Alder reaction for chemical masking and unmasking in vitro. This can be applied in complex chemical reactions and, particularly in the synthesis of biomolecules, e.g. on solid supports. The reactive components are a dienophile, particularly a trans-cyclooctene, and a diene, particularly a tetrazine.

  本发明揭示了在体外使用反电子需求Diels-Alder反应的反应组分进行化学遮蔽和解除遮蔽的方法。这可以应用于复杂的化学反应中，特别是在生物分子的合成中，例如在固体支持体上。反应组分是二烯丙烯，特别是反式-环辛烯，和二烯，特别是四唑。
• Chemically cleavable group
  申请人：Tagworks Pharmaceuticals B.V.

  公开号：US10927139B2

  公开（公告）日：2021-02-23

  Disclosed is the use of the reactive components of the inverse electron-demand Diels Alder reaction for chemical masking and unmasking in vitro. This can be applied in complex chemical reactions and, particularly in the synthesis of biomolecules, e.g. on solid supports. The reactive components are a dienophile, particularly a trans-cyclooctene, and a diene, particularly a tetrazine.

  本发明公开了利用反电子需求 Diels Alder 反应的反应组分进行体外化学掩蔽和解除掩蔽的方法。这可用于复杂的化学反应，特别是生物大分子的合成，例如在固体支持物上的合成。反应组分是亲二烯（尤其是反式环辛烯）和二烯（尤其是四嗪）。
• US9421274B2
  申请人：——

  公开号：US9421274B2

  公开（公告）日：2016-08-23